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Abstract: Weight loss (WL), as a key step of the irreversible and fatal cancer-related anorexia cachexia syndrome 
is present to some degree in 80% of non-small cell lung cancer (NSCLC) patients upon diagnosis which has been 
clearly proved to negatively alter patients’ performance status, quality of life (QOL), response to treatment, and 
prognosis. However, WL is not a problem encountered only upon diagnosis but is also commonly reported during 
the course of aggressive chemotherapy, radiotherapy (RT) and particularly the concurrent chemoradiotherapy 
(C-CRT) which may further diminish QOL measures and clinical outcomes. In general, the NSCLC literature 
has concentrated on WL during the treatment course, but recent studies have demonstrated that it is possible to 
preserve or even experience weight gain (WG) during or just short after the discontinuation of various cancer 
treatments in approximately 40% to 45% NSCLC patients. Considering the fact that recent evidence suggest a 
prognostic and predictive role for WG in anticipation of longer survival times and better response rates in weight 
gainers, this current manuscript will specifically aim to realize the actual value of WG in locally advanced and 
metastatic NSCLC patients which may potentially be added to the conventional prognostic and predictive factors 
as a novel surrogate marker of outcomes in such patients.
Keywords: Weight gain (WG); cancer treatment; non-small cell lung cancer (NSCLC); prognosis
Submitted Aug 15, 2016. Accepted for publication Aug 18, 2016.
doi: 10.21037/atm.2016.09.33
View this article at: http://dx.doi.org/10.21037/atm.2016.09.33
Since the earliest report of Hippocrates (460–377 BC), 
weight loss (WL) has been perceived as a condition that 
is closely associated with poor prognosis in patients 
presenting with chronic illnesses, including the cancer. As 
a pivotal component of the irreversible and fatal cancer-
related anorexia cachexia syndrome (CACS), WL ,is present 
to some degree in 80% of non-small cell lung cancer 
(NSCLC) patients at presentation which has been clearly 
proved to negatively alter patients’ performance status, 
quality of life (QOL), response to treatment, and prognosis 
(1,2). However, WL is not a problem encountered only 
upon diagnosis but is also commonly reported during the 
course of aggressive chemotherapy, radiotherapy (RT), and 
particularly the concurrent chemoradiotherapy (C-CRT), 
which may further diminish QOL measures and clinical 
outcomes. WL during NSCLC treatment may be associated 
with side effects including fatigue, anorexia, nausea, 
vomiting, esophagitis, early satiety, dysphagia, diarrhea, and 
infections (3).
In the August 2016 issue of Annals of Oncology Patel 
et al. (4) reported the outcomes of retrospective analysis 
of 2,301 stage IIIB or IV non-squamous NSCLC patients 
enrolled on three previous phase III clinical trials (5-7) with 
the primary endpoint of the impact of weight gain (WG) 
experienced during the treatment or at the 30-day post-
study discontinuation follow-up visit. In this commendable 
study the authors divided the 421 (18.3%) patients with 
WG into two groups: those with >5% vs. ≤5% WG. 
Majority of these patients had stage IV disease (n=340; 
81%). Their results demonstrated a significant association 
between superior median overall survival (OS) and >5% 
WG (16.7 vs.10.7 months; HR: 0.57; P<0.001). Likewise, 
the patients who experienced >5% WG had approximately 
2 months superior median progression-free survival (PFS; 
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6.9 vs. 4.8 months; HR: 0.61; P<0.001) and 25% superior 
overall response rate (50.8 vs. 25.4%; P<0.001). The 
authors also reported that these positive relationships were 
independent of other confounding variables.
Current standard treatment options for metastatic 
and locally-advanced NSCLC (LA-NSCLC) include 
systemic chemotherapy, targeted therapies, and palliative 
RT for metastatic and C-CRT for LA-NSCLC patients, 
respectively (8,9). However, starkly contrasting with the 
significant improvements in diagnostic tools and treatment 
options in the last three decades, the survival rates remained 
poor and almost constant for both the metastatic (range, 
8–12 months) and locally advanced (range, 16–24 months) 
disease stages (8-10). Given the poor outcomes in this 
patient populace, it is essential to determine prognostic 
factors beyond the conventionally utilized performance 
status, T, N, M stages, pretreatment WL, and objective 
response to treatment. Therefore, the impressive results 
of the Patel’s large retrospective review are of vital 
significance with respect to that it confirms the suggested 
novel prognostic and predictive roles for WG in NSCLC 
patients (10-12).
The particular prognostic significance of weight 
preservation or gain has previously been addressed in three 
retrospective cohort series as aforementioned above 
(10-12). In the first study reported by Sher et al. from 
Rush University Medical Center (11), the authors evaluated 
the prognostic significance of WG during the split course 
chemoradiotherapy in 92 LA-NSCLC patients with the 
primary endpoint of OS. In this study the WG was defined 
as the any weight change greater than the highest quartile 
of change (4.5 lb) between the initiation and completion 
of the CRT. The authors reported that the WG was the 
unique factor to associate with enhanced median OS times 
(51 vs. 23 months; HR: 0.5; P=0.04). At long-term, the 
OS probability was more profound in favor of the WG 
group with respective 5-year OS estimates of 50% vs. 12%. 
Second study was a smaller preoperative split-course CRT 
study again from Rush University Medical Center (12) 
which included 54 patients with locally advanced (n=51) 
or oligometastatic (n=3) LA-NSCLC patients. Results of 
multivariate analysis revealed that the initial stage (HR: 
2.94; P=0.02) and percent weight change during the CRT 
course (HR: 0.79; P<0.01) were the factors to associate with 
OS outcomes. Accordingly patients who experienced WG 
(n=26) had significantly longer median OS time compared 
to dose who did not (not reached yet vs. 16.3 months; 
P=0.001) and 3-year OS probability (71.4% vs. 21.9%). 
Although these studies suggested a survival enhancing 
function for WG during CRT course, one may contend 
that both studies utilized split-course CRT which does not 
reflect the current standard treatment paradigm for such 
patients, namely the C-CRT. In this regard, the third study 
reported by our group represents the largest of ever its kind 
study which particularly researched the impact of weight 
change during the course of exclusive radical C-CRT in 425 
stage IIIB NSCLC patients (10). In this study, in order to 
prevent uncontrollable feeding-related measurement biases, 
any WC was accepted as significant only if the calculated 
difference came upon a positive or negative body mass 
index (BMI) change of 0.5 kg/m2 relative to pretreatment 
levels. Therefore, the study population was divided into 3 
groups: group 1: WL (BMI reduction >0.5 kg/m2); group 
2: weight preservation (WP: BMI reduction/increment 
<0.5 kg/m2); and group 3: WG gain (BMI increment 
>0.5 kg/m2). However, for comparative analysis groups 2 
and 3 were consolidated as WP/G. As indicated by this 
definition, 252 patients (59.3%) experienced WL, while 
89 patients (20.9%) and 84 patients (19.8%) demonstrated 
weight preservation or gain during C-CRT. Survival 
analysis revealed that WP/G group had significantly 
superior median OS time (27.3 vs. 17.8 months; P<0.001) 
and 3-year OS rate (42.3% vs. 0%). Another important 
finding of our study was the demonstration of significantly 
longer median locoregional PFS (LRPFS: 17.4 vs . 
11.5 months) and distant metastasis free survival (DMFS 
14.1 vs. 9.3 months), which translated into longer PFS (8.7 
vs. 13.3 months) in WL patients.
Interpreting the three previous reports together with the 
more recent one by Patel et al. (4), available results suggest 
the WG experienced during C-CRT as a surrogate marker 
of superior OS times either in the preoperative split-course 
induction CRT, definitive split-course induction CRT, or 
radical C-CRT settings independent of the chemotherapy 
regimen or RT protocol in use. These results may be 
influenced by the decreased toxicity rates (particularly 
the esophagitis, nausea and vomiting) by use of more 
sophisticated RT techniques such as intensity-modulated 
or image-guided RT, earlier diagnosis and intervention 
of treatment related toxicities, and more common use of 
supportive measures. However, it is obvious that these 
complications have not been eliminated totally yet by 
utilization of more sophisticated RT techniques or available 
pharmaceutical or nutritional additives. Additionally, 
as some patients with severe toxicity do not experience 
WL and as currently available nutritional additives have 
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questionable influence on prevention or treatment of 
WL, such survival gain cannot be explained uniquely by 
decreased rates of toxicity and indicates presence of other 
potential factors to be identified. More reasonably these 
findings rather designate higher response to chemotherapy 
both as a radiosensitizer at locoregional sites and as a 
systemic treatment at distant microscopically involved 
sites (10).
Despite the exact cause(s) of association between WL 
and poorer locoregional and distant control rates is not fully 
investigated yet, impaired nutritional status, anti-tumoral 
immunity, existence of potentially unaltered chronic 
inflammatory milieu, and more aggressive tumor phenotype 
with poor or no response to any oncologic treatment may 
sensibly have assumed a part (13,14). Additionally, unaltered 
or even increased secretion of cachectic factors by poor 
or nonresponding tumors may have further contributed 
to unfavorable outcomes observed in these patients (15). 
Therefore, WG experienced during the treatment course 
may have mirrored the reversal of poor immunity, blockade 
of secretion of cachectic factors, and alteration of chronic 
inflammatory milieu in a group of NSCLC patients treated 
with various oncologic interventions. However, in order to 
conclude more reliably on this subject of critical importance 
further studies addressing this issue are urgently needed.
The value of degree of clinically significant WL has 
been clearly defined in consensus statements in order 
to create a three-stage classification specific for cancer; 
namely precachexia, cachexia, and refractory cachexia (16). 
For this purpose, the criteria for cachexia incorporates 
body WL >5% over the past 6 months or a BMI of <20 in 
combination with WL >2% over the past 6 months (16). 
However, our knowledge about the importance of degree 
of WG experienced during the cancer treatment is scarce. 
In general, previous reports did not search for a significant 
WG cutoff specific to NSCLC patients and grouped 
patients into two respective groups: those with WL or WG 
(including the weight preservers). In this respect Patel 
et al. defined “clinically significant WG” as any gain >5% 
with the aim of prevention of false measurements which 
potentially caused by daily fluctuations in hydration and 
standard error variances (4). However, authors’ additional 
analysis using “any WG” rather than 5% as the cutoff 
(n=1,066; 46.3%) demonstrated similar superior median 
OS outcomes (15.2 and 8.6 months; HR: 0.51) favoring 
the group of patients with any WG over those without. 
Comparing the HRs of two different dichotomization 
methods (0.51 vs .  0.57; for any WG vs .  >5% WG, 
respectively) reveals that preservation or gain of any body 
weight is even more important than WG >5%. Despite 
the fact that it is hard to allocate this finding to a single 
cause, yet it is rationale to hypothesize that even minor and 
clinically insignificant WG is the representative of the early 
reversal of the molecular pathways of the irreversible and 
fatal CACS.
In the two largest studies Patel et al. (4) and Topkan 
et al. (10) respectively demonstrated that it is possible 
to preserve pretreatment body weight or induce WG in 
46.3% and 40.7% of all metastatic or locally advanced 
NSCLC patients undergoing chemotherapy or C-CRT. 
Concentrating on this point, Topkan’s study is intriguing 
by exhibiting striking long-term survival rate differences at 
3-year OS (42.3 vs. 0%), LRPFS (31.2 vs. 0%), PFS (25.3% 
vs. 0%), and DMFS (26.2 vs. 0%) time points between the 
WG and WL groups, favoring the former (10). Despite 
suggesting a surrogate role for WG during C-CRT in 
accurate anticipation of outcomes in LA-NSCLC, these 
observations may further hint at tailoring adjuvant or 
salvage treatments of such patients. Because the response 
and survival outcomes were poor in the WL cohort, such 
finding may be suggestive of the need for more intense 
and efficient but less toxic adjuvant chemotherapeutics. 
Additionally, it may further suggest closer follow-up of such 
patients for earlier detection and timely management of 
resistant or recurrent local disease and/or already existing or 
de novo metastases. In the presence of stereotactic radiation 
therapy facilities, some of these patients may further 
experience tumor control, QOL, and potential survival 
benefits. On the other hand, favorable results in WG cohort 
may also raise the question about the need for potentially 
toxic and currently debated consolidation chemotherapies, 
which may not yield further clinical gain in such patients.
In conclusion, outcomes of available studies (4,10-12), 
particularly the largest of ever one by Patel et al. (4), are 
important by demonstration of a clear survival benefit with 
prevention of WL in approximately 40–45% of all NSCLC 
patients (Table 1). However, looking at the other side of 
the coin, it is dramatic to see that more than 50% of all 
NSCLC patients are continuing to lose weight despite of 
aggressive treatment. Therefore, although the potential 
therapeutic implications have not been fully exploited in 
humans, it is imperative to continue on clinical research of 
CACS for improving patients’ tolerance to treatment and 
QOL. The main goal should incorporate the development 
of both preventive and therapeutic measures for WL 
on a multidisciplinary approach basis. For this purpose, 
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considering the multifactorial nature of WL on the way of 
fatal CACS, targeting the multiple steps of CACS including 
the hypothalamic pathways, tumor-secreted factors, and 
chronic inflammation status rather than a single potential 
target appears to be of vital importance on the way of 
success.
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